nach oben laufen.ANTISOMA!
Die News von heute:
Positive data from NIH highlight broad potential in Antisoma`s targeted apoptosis programme
30 Apr 2003
[London, UK: 30 April 2003] Data showing powerful anti-tumour effects for Antisoma’s drug AS1406 (formerly Theranase) in both breast cancer and lymphoma are presented today at the Recombinant Antibodies meeting in Munich, Germany. These are the first animal data from Antisoma’s ‘targeted apoptosis’ programme, which combines antibodies that specifically target tumour cells with enzymes that trigger apoptosis or ‘programmed cell death’.
AS1406 significantly slowed the growth of primary breast tumours in a mouse model. It also inhibited the spread of breast cancer to other organs: 66% fewer secondary tumours were formed in the lungs with AS1406 than with a control. In another model, where breast cancer cells were administered into the circulation, AS1406 was associated with an 85% reduction in the number of lung tumours. AS1406 also significantly prolonged survival in a mouse model of lymphoma, a form of blood cancer. The studies were carried out by Professor Susanna Rybak at the United States National Cancer Institute under a Collaborative Research and Development Agreement between Antisoma and the US National Institutes of Health.
AS1406 is the antibody humanised HMFG1 linked to the enzyme RNase. HMFG1 is an antibody that targets and binds to a protein found on the surface of cells in many solid tumours and also on lymphomas. Previous experiments have shown that when the antibody binds to this target protein, it releases the RNase enzyme into the cancer cell, prompting the cell to ‘commit suicide’ by apoptosis. Healthy cells do not show the protein targeted by HMFG1 on their surfaces; they are therefore not exposed to the apoptosis enzyme and remain unharmed.
Professor Susanna Rybak, the lead researcher on the RNase programme said:
‘Tests have shown that AS1406 reproducibly reduces tumour burden in numerous different cancer models spanning diverse forms of the disease, providing us with a compelling case to move forwards into human clinical trials.’
Glyn Edwards, Chief Executive Officer of Antisoma, added:
“We see targeted apoptosis as a potential magic bullet for cancer, whereby we could hit cancer cells with a lethal drug whilst leaving healthy tissues unscathed. The positive data presented in Munich validate the whole concept of targeted apoptosis as a new approach to cancer therapy, one in which Antisoma has a leading position.” |
Thread abonnieren
